28506-01-6

Usage

Uses

Used in Academic and Research Applications:
1-Benzyl-3-acetamidopyrrolidine is used as an intermediate compound in organic synthesis for [application reason]. Its presence in various natural and synthetic substances makes it a valuable compound for studying chemical reactions and properties in academic and research settings.
Used in Organic Synthesis:
1-Benzyl-3-acetamidopyrrolidine is used as a building block in the synthesis of more complex organic molecules for [application reason]. Its unique structure and reactivity contribute to the development of new compounds with potential applications in various industries.

InChI:InChI=1/C13H18N2O/c1-11(16)14-13-7-8-15(10-13)9-12-5-3-2-4-6-12/h2-6,13H,7-10H2,1H3,(H,14,16)

Upstream product

• 108-24-7 acetic anhydride 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 114715-39-8 (R)-1-benzyl-3-aminopyrrolidine 
• 18471-40-4 1-Benzyl-3-aminopyrrolidine 
• 75-36-5 acetyl chloride 
• 114715-35-4 (R)-3-methanesulfonyloxy-1-(phenylmethyl)-pyrrolidine 
• 131852-53-4 (S)-1-benzyl-3-(tert-butoxycarbonylamino)pyrrolidine 
• 114715-38-7 (3S)-1-benzyl-3-pyrrolidinamine 
• 114636-29-2 (3S)-3-azido-1-(phenylmethyl)pyrrolidine 

Downstream Products

• 79286-74-1 3-acetylaminopyrrolidine 
• 114715-37-6 (3'R)-7-(3'-aminopyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride 

Relevant academic research and scientific papers

Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor

A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib's core structure, (3R,4R)-3-amino-4-methylpiperidine. From the new core structures, we selected (R)-N-methyl-N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a scaffold for further SAR studies. From biochemical enzyme assays and liver microsomal stability tests, (R)-3-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile (6) was chosen for further in vivo test through oral administration. Compound 6 showed improved selectivity for JAK1 compared to that of tofacitinib (IC50 11, 2.4 × 102, 2.8 × 103, and 1.1 × 102 nM for JAK1, JAK2, JAK3, and TYK2, respectively). In CIA and AIA model tests, compound 6 exhibited similar efficacy to tofacitinib citrate.

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs

A series of analogs of DM235 and MN19, characterized by rings with different size, have been prepared and evaluated for their nootropic activity in the mouse passive-avoidance test. It was found that the optimal ring size for the analogs of DM235, showing endocyclic both amidic groups, is 6 or 7 atoms. For the compounds structurally related to MN19, carrying an exocyclic amide group, the piperidine ring is the moiety which gives the most interesting compounds.

BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and/or diabetes.

An efficient conversion of chiral α-amino acids to enantiomerically pure 3-amino cyclic amines

Enantiomerically pure 3-amino cyclic amines such as 3-amino pyrrolidine, 3-amino piperidine, and 2,3,4,5,6,7-hexahydro-1H-azepine have been synthesized in high yields from the optically active natural α-amino acids such as L-aspartic acid, L-glutamic acid, L-2-aminoadipic acid, and their enantiomers.

Quinolinecarboxylic acid derivatives and antibacterial agent containing the same

Novel quinolinecarboxylic derivatives of the formula: STR1 wherein Z is STR2 in which R1 is hydrogen atom or a lower alkyl, R2 is hydrogen atom, hydroxyl or a lower alkyl and R3 is hydrogen atom, hydroxyl or an amino, and

Asymmetric Synthesis and Properties of the Enantiomers of the Antibacterial Agent 7-(3-Aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic Acid Hydrochloride

Compound 1 is a potent member of the quinoloecarboxylic acid class of antibacterial agents and is currently undergoing clinical evaluation.We have developed efficient asymmetric syntheses of the enantiomers of this agent.The S-(+) enantiomer 1a is 1-2 log2 dilutions more active than the R-(-) enantiomer 1b against aerobic bacteria and 1-2 or more log2 dilutions more active against anaerobic bacteria in vitro.The enantiomer 1a shows significantly better in vivo activity in a Pseudomonas aeruginosa mouse protection model compared to racemic 1.Coupled with the improved solubility profile of 1a relative to racemic material, these features may be of practical significance from a clinical standpoint.